IPS Cell therapies that evade the immune system

Shinobi engineers immune evasive and armored iPSCs to unlock the full potential of cell therapies.
Scroll down

What if a cell therapy could work with the immune system rather than against it?  

iPSC therapies hold immense potential to cure cancer and other devastating diseases, but their success is often limited by rejection by the patient’s immune system.

This is Shinobi, the first iPS cell therapy compatible with the patient’s immune system.

Shinobi’s immune evasion technology not only shields from innate immune attack but also against antibody-mediated rejection. 

Technology

Silent. Precise. Potent. The next generation of cell therapies is here.

NJA-001

iPS-ɑβ T cell
HCC, CRC, NSCLC

NJA-201

iPS-NK cell
Autoimmune diseases

NJA-301

iPS-ɑβ T cell
Glioblastoma

Pipeline

“Shinobi's Katana platform has the potential to make CAR-T cell therapies accessible to patients on a global scale.”

Dr. Carl June, M.D.
Pioneer of CAR-T cell therapy and member of Shinobi’s Scientific Advisory Board
Map of Kyoto, Japan and San Francisco, CaliforniaMap of Kyoto, Japan and San Francisco, California

With roots in Kyoto and UCSF, we’re led by an unrivaled team of industry leaders and pioneers.

Team

Shinobi Publications

Our technology has been validated in numerous publications. Most recently…

2023

Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity.

Deuse Lab / Shinobi Therapeutics, Cell Stem Cell
2023

Mini-TCRs: Truncated T cell receptors to generate T cells from induced pluripotent stem cells.

Kaneko Lab / Shinobi Therapeutics, Molecular Therapy Methods & Clinical Development

Pipeline

Sharing its name with the Japanese term for ‘ninja’, Shinobi has aptly named its pipeline ‘NJA’.

NJA-001 (CD8⍺β T cell)

GPC3+ HLA-A24 solid tumors
Discovery
Preclinical
Clinical
Preclinical

NJA-002 (CD8⍺β T cell)

Undisclosed TCR for solid tumors
Discovery
Preclinical
Clinical
Preclinical

NJA-003 (CD8⍺β T cell)

GPC3+ HLA-A2 solid tumors
Discovery
Preclinical
Clinical
Discovery

NJA-004 (CD8⍺β T cell)

Undisclosed CAR for autoimmune diseases
Discovery
Preclinical
Clinical
Preclinical

NJA-005 (Pancreatic beta cell)

Type 1 Diabetes
Discovery
Preclinical
Clinical
Discovery

Partnerships

Shinobi partners with top-tier institutions to consistently source and advance groundbreaking research in immune evasive iPSC-derived cell therapies.

Learn More

Join us in pioneering the next frontier of cell therapy

LinkedIn